New latency-promoting agents for a block-and-lock functional cure strategy.
Curr Opin HIV AIDS
; 19(3): 95-101, 2024 05 01.
Article
in En
| MEDLINE
| ID: mdl-38457209
ABSTRACT
PURPOSE OF REVIEW Currently, HIV-infected patients are treated with antiretroviral therapy. However, when the treatment is interrupted, viral rebound occurs from latently infected cells. Therefore, scientists aim to develop an HIV-1 cure which eradicates or permanently silences the latent reservoir. RECENT FINDINGS:
Previously, scientists focused on the shock-and-kill cure strategy, which aims to eradicate the latent reservoir using latency-reactivating agents. Limited success shifts the interest towards the block-and-lock cure approach, which aims to achieve a functional cure by "blocking" HIV-1 transcription and "locking" the provirus in a deep latent state, resistant to treatment-interruption. In this strategy, latency promoting agents are used to induce transcriptional silencing and alter the epigenetics environment at the HIV promotor.SUMMARY:
For the block-and-lock cure strategy to succeed more investigation into the transcriptional and epigenetic regulation of HIV-1 gene expression is necessary to design optimal latency-promoting agents. In this review, we will discuss the latency promoting agents that have been described in literature during the past 2 years (2022-2023).
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Virus Activation
/
HIV Infections
Limits:
Humans
Language:
En
Journal:
Curr Opin HIV AIDS
/
Curr. opin. HIV AIDS
/
Current opinion in HIV and AIDS
Journal subject:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: